NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.93 -0.08 (-0.47 %)
(As of 06/18/2018 11:55 AM ET)
Previous Close$16.70
Today's Range$16.67 - $17.03
52-Week Range$15.66 - $48.87
Volume10,142 shs
Average Volume364,373 shs
Market Capitalization$598.91 million
P/E Ratio-3.15
Dividend YieldN/A
Beta3.41

About Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics logoFive Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. Its product candidates also comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor IIb, which is in Phase I clinical trials to treat patients with gastric or gastroesophageal junction and bladder cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 as a monotherapy in various cancers. The company's FP-1039 is in Phase Ib clinical trials to treat patients with malignant pleural mesothelioma. Its preclinical product candidates include FPA150, a CD8 T cell checkpoint inhibitor antibody; FPA154, a tetravalent agonistic antibody that activates glucocorticoid-induced tumor necrosis factor receptor; and FPT155, a CD80-Fc fusion protein, which modulates signaling pathways. The company has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with bluebird bio, Inc., Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. Five Prime Therapeutics, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

Receive FPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FPRX
CUSIPN/A
Phone415-365-5600

Debt

Debt-to-Equity RatioN/A
Current Ratio9.79
Quick Ratio9.79

Price-To-Earnings

Trailing P/E Ratio-3.15
Forward P/E Ratio-3.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.51 million
Price / Sales15.09
Cash FlowN/A
Price / CashN/A
Book Value$7.80 per share
Price / Book2.17

Profitability

EPS (Most Recent Fiscal Year)($5.38)
Net Income$-150,220,000.00
Net Margins-221.74%
Return on Equity-44.36%
Return on Assets-36.14%

Miscellaneous

Employees216
Outstanding Shares35,210,000

Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics Inc (NASDAQ:FPRX) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.08. The biotechnology company had revenue of $32.49 million for the quarter, compared to analysts' expectations of $37.50 million. Five Prime Therapeutics had a negative net margin of 221.74% and a negative return on equity of 44.36%. View Five Prime Therapeutics' Earnings History.

What price target have analysts set for FPRX?

7 analysts have issued 1-year price objectives for Five Prime Therapeutics' shares. Their predictions range from $17.00 to $60.00. On average, they anticipate Five Prime Therapeutics' stock price to reach $34.7143 in the next year. View Analyst Ratings for Five Prime Therapeutics.

Who are some of Five Prime Therapeutics' key competitors?

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the folowing people:
  • Dr. Lewis T. Williams, Founder & Exec. Chairman (Age 69)
  • Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 49)
  • Dr. Kevin P. Baker, Sr. VP of Devel. Sciences (Age 57)
  • Dr. Peder K. Jensen, Advisor & Director (Age 63)
  • Mr. Jeff P. Coon, Sr. VP of HR (Age 55)

Has Five Prime Therapeutics been receiving favorable news coverage?

Media headlines about FPRX stock have trended somewhat positive recently, Accern reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a coverage optimism score of 0.05 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.36 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Five Prime Therapeutics' major shareholders?

Five Prime Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.56%), Victory Capital Management Inc. (3.04%), Dimensional Fund Advisors LP (2.96%), BB Biotech AG (2.78%), Rock Springs Capital Management LP (1.66%) and Northern Trust Corp (1.05%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.

Which institutional investors are selling Five Prime Therapeutics stock?

FPRX stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Citigroup Inc., Spark Investment Management LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Five Prime Therapeutics.

Which institutional investors are buying Five Prime Therapeutics stock?

FPRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rock Springs Capital Management LP, BB Biotech AG, DekaBank Deutsche Girozentrale, Victory Capital Management Inc., Millennium Management LLC, UBS Group AG and State of Wisconsin Investment Board. View Insider Buying and Selling for Five Prime Therapeutics.

How do I buy shares of Five Prime Therapeutics?

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of FPRX stock can currently be purchased for approximately $16.93.

How big of a company is Five Prime Therapeutics?

Five Prime Therapeutics has a market capitalization of $598.91 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe.

How can I contact Five Prime Therapeutics?

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600.


MarketBeat Community Rating for Five Prime Therapeutics (FPRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  376
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.